Research Article - Biomedical Research (2017) Volume 28, Issue 13

Association between hepatitis C virus genotypes, liver function and serum lipid levels of chronic hepatitis C patients in a Chinese population

Zhang Hong-mei¹, Ma Ying¹, Ni Jun-ming¹, Zhang Xiao-yu¹ and Chu Li-li^2*

¹Clinical Research Center, the Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu, PR China

²Pediatric Research Institute, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China

*Corresponding Author:

Chu Li-li
Pediatric Research Institute
Children's Hospital of Nanjing Medical University, PR China

Accepted on May 22, 2017

Abstract

Background: This study was aimed at investigating the distribution of hepatitis C virus (HCV) genotypes in a Chinese population as well as establishing any association between these genotypes and liver function or serum lipid levels among chronic hepatitis C patients.

Methods: A total of 231 HCV RNA positive patients in the South Eastern area of China were enrolled in this study. HCV RNA and HCV genotyping were determined by fluorescent quantitative polymerase chain reaction and gene chip, respectively. An automatic biochemical analyser (HITACH7600-120) was used for assessing liver function and indicators of lipid metabolism.

Results: Genotype 1b was the most common subtype of HCV (77.1%). There were significant differences in viral loads among different kinds of HCV (F=3.292, P=0.012). No significant relationship was observed between HCV genotype and liver function indicators (P>0.05). Apo lipoprotein-B level of patients infected with HCV 3b was lower than those infected with HCV 1b (P=0.003) and HCV 1b/2a (P=0.046). Total cholesterol level in HCV 3b patients was lower than in those infected with HCV 1b (P=0.001) and HCV 2a (P=0.004).

Conclusions: Genotype 1b was most prevalent in some regions of China. HCV genotypes were not associated with liver function, but related to serum lipid levels of Chinese chronic hepatitis C patients.

Keywords

Chronic hepatitis C, Genotype, Liver function, Serum lipid levels, Viral loads.

Introduction

Approximately 170 million people are reported to be infected with hepatitis C virus (HCV) worldwide [1]. In China, 38 million people are HCV carriers (about one-fourth of the world’s total), and the figure is increasing rapidly every year [2,3]. HCV infection causes acute or chronic hepatitis, may degenerate to liver fibrosis, liver cancer and metabolic disorders [4,5]. There are considerable variations in the extent of liver damage, extra-hepatic manifestations, efficacy of antiviral treatment, and disease outcome of patients with different HCV genotypes [6-8]. Although the effect of lipid metabolism on the progress of chronic hepatitis C has been investigated in many studies [9,10], differences in serum lipid metabolism of patients with different HCV genotypes remain unclear.

In this study, we investigated the distribution of HCV genotypes in Chinese chronic hepatitis C patients admitted in our hospital, and compared the differences in HCV genotypes and liver function or serum lipid levels among chronic hepatitis C patients in China. It is hoped that the results of our study can serve as a basis for the selection of appropriate treatment protocols, courses, and decision making for the prevention of chronic hepatitis C outbreaks in China and in other areas.

Materials and Methods

Patient selection

A total of 231 HCV RNA positive patients (male: 137, female: 94, age: 17-82 y) seen from June 2009 to October 2015 in the South Eastern area of China were enrolled in this study. Serum samples were stored in a refrigerator (-80°C) within 2 h after blood sampling. Patients with HAV, HBV, HDV, or HEV infection are excluded. Diagnosis of chronic hepatitis C was made according to the Guideline on the Prevention and Treatment of Hepatitis C (2004) issued by the Hepatology Department and Department of Infectious and Parasitic Diseases, Chinese Medical Association [6]. All the patients were duly informed about the study, and they gave informed consent.

Examination method

HCV genotyping was conducted according to the operating manual of HCV genotyping chip provided by the Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences. RNA extraction, reverse transcription, and nested Polymerase Chain Reaction (PCR) were carried out.

The PCR product was denatured and dropped in the sampling zone of the chip. Hybridization was performed in a thermostat at 42°C for 30 min. After film coloration, scanning was done using an optical scanner, and the results were interpreted with HCV gene analyzing software.

HCV RNA was detected using Q-PCR method according to the operating manual of the test kit provided by Kehua (Shanghai) Bioengineering, while HCV RNA load was detected with LightCycler480 PCR system (Roche). An automatic biochemical analyser (HITACH7600-120) was employed for assessing liver function and indicators of lipid metabolism, including Gamma-Glutamyltransferase (GGT), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Low Density Lipoprotein-Cholesterol (LDL-C), Apo-lipoprotein (Apo)-AI, Apo-B, Total Cholesterol (TC), and Triacylglycerol (TG).

Statistical analysis

Data was analysed by SPSS 19.0. Measurement data are presented as ͞x ± s. Variance analysis was done after a homogeneity test of variances, and comparison of the average of the two was made through Post Hoc t-test. Enumeration data were analysed through chi-square test. Statistical difference was assumed whens P<0.05.

Results

Distribution of HCV genotype in chronic HC patients

In 231 samples, HCV 1b was the most common genotype (77.1%), followed by HCV 3b (10.8%), HCV 2a (7.4%), HCV 1b/2a (3.5%), and HCV 3a (1.3%). The proportions of genotypes, gender, and age distribution are shown in Table 1.

Table 1. Distribution of HCV genotypes and comparison of viral loads of patients.

Comparison of HCV RNA among different HCV genotypes

Results for HCV RNA load are shown on Table 2. Comparison of HCV RNA among different genotypes, through ANOVA, demonstrated a significant difference (F=3.292, P=0.012). Post Hoc t test showed a significant difference in HCV RNA loads between HCV 1b and HCV2a; HCV 1b and HCV 1b/2a; HCV 3b and HCV2a, and between HCV 3b and HCV 1b/2a (P<0.05).

Table 2. Viral load of different HCV genotypes.

Liver function of patients with different HCV genotypes

The result of the liver function examination indicates that 79.65% (184/231) of patients demonstrate abnormal values of one or more indicators. As shown in Table 3, there are no significant correlations between HCV (F=0.132, P=0.970) genotype and GGT(F=0.303, P=0.876), ALT, and AST (F=0.247, P=0.911).

Table 3. GGT, ALT, and AST of patients in the various HCV genotypes.

Lipid metabolism in patients with different HCV genotypes and correlation analysis

About 28.57% of the 231 patients had abnormal values of one or more indicators of lipid metabolism. There was no significant difference in the LDL-C (F=1.386, P=0.240), Apo- AI (F=1.310, P=0.267), and TG (F=1.047, P=0.384) levels of patients infected with different HCV genotypes. However, Apo-B (F=2.422, P=0.049) and TC (F=3.163, P=0.015) of patients with different HCV genotypes were not exactly the same (Table 4).

Table 4. LDL-C, Apo-AI, Apo-B, TG, and TC of patients with different HCV genotypes.

Further Post Hoc comparison of Apo-B and TC revealed that the expression of Apo-B in patients with 3b HCV genotype was lower than in those with 1b and 1b/2a genotypes (P=0.003, P=0.046 respectively), indicating that the TC levels of patients with 3b HCV genotype were lower than those with 1b (P=0.001) and 2a (P=0.004) genotypes (Table 5).

Table 5. Pairwise comparison of the Apo-B and TC level of patients with different HCV genotypes.

Discussion

China has approximately 40 million HCV carriers, which is about one-fourth of the world’s total [2]. Genotyping test is especially valuable in deciding the course of treatment of HCV. Therefore, monitoring HCV genotype and serum viral load is of great clinical significance in the treatment of chronic HCV [6]. China has four prevailing HCV genotypes: types 1, 2, 3, and 6. Types 1b and 2a are predominant in northern part of China, while types 3 and 6 have spread rapidly in the south and south-western regions in recent years [11]. In this study, 5 HCV genotypes/subtypes were identified (1b, 3b 2a, 3a and 1b/ 2a). The fact that HCV 1b was the primary genotype is consistent with most domestic and foreign reports [11]. However, HCV 3b was more preponderant than HCV 2a, indicating the spread of HCV genotypes from injection drugs users to the normal population [11-13].

In comparing results of viral load of different genotypes, a significant difference was observed between HCVs 1b and 2a, 1b and 1b/2a, 3b and 2a, and 3b and 1b/2a. HCV 1b and 3b had similar viral load, which is higher than that of HCV 2a and HCV 1b/2a. Combination of pegylated interferon-α and Ribavirin is considered a standard antiviral protocol for the treatment of chronic HC. Types 1b and 2a are the prevailing HCV genotypes in China. Genotype 1b has low Sustained Virologic Response (SVR) to interferon and a high recurrence rate, and it needs a long course of treatment. Conversely, genotype 2a has a good response to interferon, low recurrence rate, and can be treated through antiviral methods. The viral content of genotype lb was significantly higher than that of 2a. This may be one of the reasons why genotype 1b demonstrates poor response to interferon [14].

About 80% of patients with HCV infection develop chronic disease if they are not treated correctly and promptly after infection [15]. At least 50%-70% of the patients exhibit continuous increases in plasma transaminase levels. In severe cases, manifestations of cirrhosis or even primary liver cancer may be present [16]. Among the 231 chronic HC patients enrolled in this study, 184 had abnormal values of one or more indicators of liver function. This finding indicates a certain degree of liver damage in most chronic HC patients. However, no evidence can be found supporting the correlation between degree of liver damage and HCV genotype. In a study elsewhere, patients with genotype 1 HCV tended to manifest greater and more chronic increases in ALT [16]. Higher ALT levels have been reported in patients with genotype 2a HCV than those with genotype 1b HCV, indicating possibility of higher level of liver damage in patients infected with genotype 2a HCV [17]. In another study, no difference in ALT level is reported between patients infected by genotype 1 HCV and those by HCV of other genotypes, and no significant difference in ALT, AST, and other indicators of liver function is observed in patients affected by HCV of different genotypes [18]. In the current study, no significant differences were seen in the three main indicators of liver function (GGT, ALT, and AST) in patients infected by different HCV genotypes This indicates that there is no direct correlation between genotype of HCV and liver damage. These variations may be due to the relatively large number of factors that affect ALT, AST and GGT, the correlation between degree of liver damage and immunoreaction of patients, and the differences in the distributions of HCV genotypes in different countries and regions. To make an objective judgment, more data on HCV genotypes are required.

Recent studies revealed a high correlation between HCV infection and liver lipid metabolism [19]. Among the factors that influence the outcome and efficacy of treatment of chronic HC patients, lipid metabolism has attracted more attention recently. Disorders in lipid metabolism are common in chronic HC patients. Studies have shown that 70.5% of chronic HCV carriers have some degrees of hyperlipidemia, the incidence of which is related to HCV replication [20]. Abnormal lipid metabolism in chronic HC patients infected by the genotype 3 HCV is mainly due to viral factors. For patients infected by HCV of other genotypes, abnormal lipid metabolism is mainly due to host factors [21]. Lipid metabolism disorder also affects continuous response to anti-HCV drugs. Before treatment, the TG and LDL-C level of patients are independently associated with SVR [22]. In the treatment of patients infected by the genotype 3 HCV using interferon-α2a (180 μg/w) and Ribavirin (10 mg/kg/d), the SVR of patients with abnormal lipid metabolism (43.7%) is significantly lower than that of patients with normal lipid metabolism (72.2%) [9].

In this study, the percentages of patients with abnormal lipid metabolism in the different HCV genotypes were 23.38% (1b); 1.73% (3b), 35.29% (2a), 25% (1b/2a), and 66.67% (3a). Except for that of patients carrying the genotype 3a HCV (only three cases), the level of dyslipidemia in chronic HC patients enrolled in this study was not as high as that reported elsewhere outside China. However, the LDL-C, Apo-B, and TC of 3a and 3b HCV carriers were lower than those of the carriers of HCV of other genotypes. Moreover, there was a significant difference in Apo-B and TC between 3b HCV carriers and carriers of other HCV genotypes, and a high correlation between the two. 3b HC patients had lower Apo-B and TC but significantly higher viral load than 2a and 1b/2a HC patients. A negative correlation between serum Apo-B level and HCV viral load has been reported, and the mechanism is related to cellular infection by HCV [23]. HCV does not combine with hepatic cells directly. They combine with TC and Apo-B, among others, in serum to form lipophilic virus-like particles. HCV particles wrapped by lipoproteins enter and infect hepatic cells through the combination with LDL receptor (LDLR) on the membrane of the hepatic cell. By combining with LDLR, serum Apo-B and LDL competitively inhibit the internalization of HCV particles. Thus, the serum viral load increases along with decrease in serum Apo-B, TC, and LDL [24].

Conclusion

In this study, HCV 1b was the most prevalent genotype seen in chronic HC patients admitted in our hospital, followed by 3b and 2a. Chronic HCV infection caused liver damage and lipid metabolism disorder. Although no significant difference in liver function was found in patients infected by different genotypes of HCV, patients infected by 1b HCV had higher viral loads while patients infected by genotype 3 HCV had higher incidence of abnormal lipid metabolism.

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 81300323).

Conflict of Interest

We declare that there are no conflicts of interest in this research.

References

1. Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ. Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol 2013; 59: 1073-1080.
2. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Org 2012; 90: 540-550.
3. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008; 122: 990-1003.
4. Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2012; 14: 8-16.
5. Jung HJ, Kim YS, Sang GK, Yun NL, Jeong SW, Jang JY. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol 2014; 20: 38-46.
6. Chinese Society of Hepatology CMA. The guidelines of prevention and treatment for chronic hepatitis B. Chinese J Hepatol 2005; 13: 881-891.
7. Munir S, Saleem S, Idrees M, Tariq A, Butt S. Hepatitis C treatment: current and future perspectives. Virol J 2010; 7: 296.
8. Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM 2010; 103: 293-303.
9. Aziz H, Gill U, Raza A, Gill ML. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients. European Gastroenterol J 2014; 26: 538-543.
10. Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S. Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2. Gastroenterol Res Pract 2012; 2012: 1-7.
11. Zhao L, Feng Y, Xia XS. The different epidemic and evolution of HCV genotypes. Yi Chuan 2012; 34: 666-672.
12. Zhou YQ, Wang XH, Mao Q, Fan Y, Zhu Y, Zhang XQ. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J Clin Virol 2009; 46: 230-233.
13. Zhang C, Wu N, Liu J, Ge Q, Huang Y, Ren Q. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. Plos One 2011; 6: 16817.
14. Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J. Viral Hepat 2009; 16: 833-843.
15. Rjf VC, Soldevila-Pico C, Morelli G, Cabrera R, Levy C. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071.
16. Enrico S, Fulvia B, Agostino C, Antonella C, Savino B, Sonia R. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-290.
17. Mao X, Peng X, Zhang Y, Li L. Association of hepatitis C virus genotype with glycolipid iron metabolism in Gansu Han population. J Zhejiang Univ Med Sci 2013; 42: 345-349.
18. Zhou Q, Li Y, Tong Y. Patients with hepatitis C for genotyping, liver function and blood analysis in Wuhan area. Int J Lab Med 2013.
19. Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 †the new treatment challenge. Aliment Pharmacol Ther 2014; 39: 686-698.
20. Murthy GD, Vu K, Venugopal S. Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection. European Gastroenterol J 2009; 21: 902-907.
21. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatol 2002; 36: 1266-1272.
22. Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-863.
23. Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RDG. Lipids and HCV. Semin Immunopathol 2012.
24. Kai Y, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J Med Virol 2013; 85: 1180-1190.